Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00711828 · FLOW

Participant flow

Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma · Source last updated 2019-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Rituximab 375 mg/m2 IV on day 1\> Cyclophosphamide 300 mg/m2 PO on days 1, 8, 15, 22\> Bortezomib 1.3 mg/m2 IV on days 1, 8, 15, 22\> Dexamethasone 40 mg PO on days 1, 8, 15, 22
    id
    FG000
    title
    Treatment
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        21
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        21
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Rituximab 375 mg/m2 IV on day 1\> Cyclophosphamide 300 mg/m2 PO on days 1, 8, 15, 22\> Bortezomib 1.3 mg/m2 IV on days 1, 8, 15, 22\> Dexamethasone 40 mg PO on days 1, 8, 15, 22
    id
    FG000
    title
    Treatment
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        21
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        21
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice